Real Clinics. Real Patients. Real Oncology.

Clinical Trials

CONVERGE-01 Shows Promising Activity With Ac-225 Rosopatamab Tetraxetan After Lu-PSMA Therapy

July 1, 2026
c
Listen to this
article

A Next-Generation PSMA-Directed Approach

Patients with metastatic castration-resistant prostate cancer (mCRPC) who progress after lutetium-177 prostate-specific membrane antigen (Lu-PSMA) radioligand therapy have limited treatment options. Part 3 of the phase 2 CONVERGE-01 study evaluated CONV01-α, an actinium-225 (Ac-225) alpha-emitting radionuclide conjugated to the PSMA-directed monoclonal antibody rosopatamab, in a population previously exposed to Lu-PSMA.

The slide presentation highlighted several potential features of this radioantibody platform. Compared with small-molecule radioligands, antibody-based biodistribution may reduce uptake in the salivary glands and kidneys, while providing longer circulation and tumor retention. Ac-225 also has a 10-day half-life that complements antibody targeting. CONV01-α was administered in 2 doses, on days 1 and 15, on a fractionated regimen previously evaluated in investigator-initiated studies.

Study Design and Patient Population

Eligible patients had progressive mCRPC, at least 1 PSMA PET-positive metastatic lesion, and no PSMA PET-negative lesions. Participants had previously received at least 1 androgen receptor pathway inhibitor (ARPI), 1 or 2 taxane regimens, and Lu-PSMA therapy. Prior PARP inhibitors, radium-223, or platinum chemotherapy were not permitted.

The presentation reported 35 treated patients with a median age of 72 years. Bone metastases were present in 89%, distant lymph-node disease in 31%, liver metastases in 3%, and other disease sites in 6%. All patients had received an ARPI; 80% had received 1 taxane regimen, and 77% had received ≥4 cycles of Lu-PSMA. Nearly half had a history of xerostomia.

Manageable Safety Without Dose-Limiting Toxicity

No dose-limiting toxicities were reported. Most treatment-emergent adverse events were grade 1 or 2 and were generally hematologic, digestive, or constitutional. Grade 3 events were described as clinically manageable and transient, and no treatment-related event led to discontinuation. All high-grade anemia occurred in patients who were already transfusion dependent.

Thrombocytopenia was characterized as predictable, dose related, and clinically manageable, with an early platelet nadir followed by evidence of recovery and little evidence of clinical risk. Imaging showed that CONV01 was not visualized in the salivary glands or urinary system. The presentation also reported no nephrotoxicity or high-grade xerostomia, findings of particular interest after prior Lu-PSMA exposure.

Early Antitumor Activity and Durability

Among 25 evaluable patients, 10 (40%) achieved a prostate-specific antigen (PSA) decline of ≥50%. PSA50 rates were similar across exposure groups, but the target-dose group showed greater durability in the time-on-study analysis. Responses were observed in patients who had received either 1 to 3 or ≥4 prior cycles of Lu-PSMA.

In the efficacy subset treated at the target dose, preliminary median radiographic progression-free survival was 8.41 months, with a median follow-up of 8.14 months. The investigators selected the target dose range, corresponding to 9.0 MBq in the slide presentation, based on the combined safety, activity, and durability findings.

Takeaways and Next Steps

Further study will need to confirm the durability of response, radiographic disease control, and longer-term safety, including cumulative hematologic effects. CONVERGE-01 continues in taxane- and Lu-PSMA-naive patients, and a pivotal phase 3 study is in preparation for patients previously exposed to Lu-PSMA. For now, CONV01-α represents a promising investigational option in a population with substantial unmet need.

Sources

Morris MJ, George DJ, Gupta S, et al. CONVERGE-01: phase 2 study of Ac-225 rosopatamab tetraxetan (CONV01-α). Lu-PSMA-pretreated metastatic androgen pathway modulator-resistant prostate cancer. Presented at: 2026 American Society of Clinical Oncology Annual Meeting. Abstract 5011. Slide presentation.

Morris MJ, George DJ, Gupta S, et al. CONVERGE-01 part 3: Ac-225 rosopatamab tetraxetan (CONV01-α) in Lu-PSMA-pretreated metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2026;44:(suppl). Abstract 5011. doi:10.1200/JCO.2026.44.16_suppl.5011

Share this article

Oncology is evolving.
  Stay current.  

Weekly breakthroughs, expert insights, and clinical updates —delivered to your inbox.

Further Reading

What are you
looking for?

POPULAR SEARCHES